Holds one active US DMF for letermovir, filing since 2021. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 30 markets.
Holds one active US DMF for letermovir, filing since 2026. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 4 markets.
Holds one active US DMF for letermovir, filing since 2021. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 25 markets.
Holds one active US DMF for letermovir, filing since 2025. Its 2024 FDA inspection closed as NAI, and its GMP is recognised in 2 markets.
Holds one active US DMF for letermovir, filing since 2025. Its 2024 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Holds one active US DMF for letermovir, filing since 2024. Its 2024 FDA inspection closed as NAI.
Holds one active US DMF for letermovir, filing since 2024. Its 2023 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Holds one active US DMF for letermovir, filing since 2025. Its 2019 FDA inspection closed as VAI, and its GMP is recognised in 2 markets.
The names are listed below. Ask Fred about the filings, inspection history and GMP certificates on record for each manufacturer.
Contract manufacturers make to order rather than holding their own filing for this molecule.
The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Every factor appears on the card it produced. Read the full method.
Ask Fred which manufacturers are on record for letermovir and what filings they hold.
Chat with Fred, your AI analyst